UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): April 12, 2005


                                  NovaMed, Inc.
               --------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)


         Delaware                           0-26625              36-4116193
----------------------------             ------------        -------------------
(State or Other Jurisdiction             (Commission            (IRS Employer
     of incorporation)                   File Number)        Identification No.)


980 North Michigan Avenue, Suite 1620, Chicago, Illinois                 60611
--------------------------------------------------------              ----------
     (Address of Principal Executive Offices)                         (Zip Code)


        Registrant's telephone number, including area code (312) 664-4100

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act
<PAGE>

Section 4 - Matters Related to Accountants and Financial Statements

Item 4.01. Changes in Registrant's Certifying Accountant.

(a)(i) On April 12, 2005,  PricewaterhouseCoopers LLP ("PwC") notified the Audit
Committee of the Board of  Directors of NovaMed,  Inc.  (the  "Company")  of its
decision to resign as the Company's  independent  registered  public  accounting
firm, effective immediately.

(ii) The reports of PwC on the Company's  financial  statements for the past two
fiscal years  contained no adverse opinion or disclaimer of opinion and were not
qualified or modified as to uncertainty, audit scope or accounting principle.

(iii) During the two most recent fiscal years and through April 12, 2005,  there
have been no  disagreements  with PwC on any matter of accounting  principles or
practices,  financial  statement  disclosure,  or auditing  scope or procedures,
which  disagreements,  if not resolved to the  satisfaction  of PwC,  would have
caused them to make reference thereto in its reports on the financial statements
for such years.  During the two most recent  fiscal years and through  April 12,
2005,  there were no  reportable  events (as  defined  in Item  304(a)(1)(v)  of
Regulation S-K).

(iv) The Company has requested PwC to furnish it with a letter  addressed to the
Securities  and Exchange  Commission  stating  whether or not it agrees with the
above  statements  made by the Company in this Form 8-K. A copy of PwC's letter,
dated April 18, 2005, is filed as Exhibit 16.1 to this Form 8-K.

(b) On April 12, 2005,  the Audit  Committee of the Board of Directors  approved
the  appointment  of BDO  Seidman,  LLP  ("BDO")  as the  Company's  independent
registered public accounting firm,  effective  immediately.  During the two most
recent fiscal years and through April 12, 2005, the Company did not consult with
BDO  regarding  (i) the  application  of  accounting  principles  to a specified
transaction,  either completed or proposed;  (ii) the type of audit opinion that
might be rendered on the Company's financial  statements;  and neither a written
report  was  provided  to the  Company  nor oral  advice was  provided  that BDO
concluded  was an  important  factor  considered  by the  Company in  reaching a
decision as to the accounting,  auditing or financial  reporting issue; or (iii)
any matter  that was either the  subject of a  disagreement  (as defined in Item
304(a) (1) (iv) of  Regulation  S-K) or a  reportable  event (as defined in Item
304(a) (1) (v) of Regulation S-K).

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(c)   Exhibits

                  Exhibit Number    Title
                  --------------    -------------

                  16.1              Letter  from  PwC  to  the   Securities  and
                                    Exchange  Commission  dated  April 18,  2005
                                    regarding change in certifying accountant

                  99.1              Press release of NovaMed,  Inc.  dated April
                                    18, 2005
<PAGE>

                                    SIGNATURE

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                 NovaMed, Inc.


Dated: April 18, 2005                            By: /s/ Scott T. Macomber
                                                    ----------------------------
                                                    Scott T. Macomber
                                                    Executive Vice President and
                                                    Chief Financial Officer
<PAGE>

                                  EXHIBIT INDEX

Exhibit No.       Exhibit
-----------       -------

16.1              Letter  from PwC to the  Securities  and  Exchange  Commission
                  dated April 18, 2005 regarding change in certifying accountant

99.1              Press release of NovaMed, Inc. dated April 18, 2005
{"company-data": {"conformed-name": "NOVAMED INC", "cik": "0001086939", "assigned-sic": "8741", "irs-number": "364116193", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26625", "film-number": "05757300"}, "business-address": {"street1": "980 N MICHIGAN AVENUE", "street2": "SUITE 1620", "city": "CHICAGO", "state": "IL", "zip": "60611", "phone": "3126644100"}, "mail-address": {"street1": "980 N MICHIGAN AVENUE", "street2": "SUITE 1620", "city": "CHICAGO", "state": "IL", "zip": "60611"}, "former-company": {"former-conformed-name": "NOVAMED EYECARE INC", "date-changed": "19990521"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): April 12, 2005

                                  NovaMed, Inc.
               --------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

         Delaware                           0-26625              36-4116193
----------------------------             ------------        -------------------
(State or Other Jurisdiction             (Commission            (IRS Employer
     of incorporation)                   File Number)        Identification No.)

980 North Michigan Avenue, Suite 1620, Chicago, Illinois                 60611
--------------------------------------------------------              ----------
     (Address of Principal Executive Offices)                         (Zip Code)

        Registrant's telephone number, including area code (312) 664-4100

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act
Section 4 - Matters Related to Accountants and Financial Statements

Item 4.01. Changes in Registrant's Certifying Accountant.

(a)(i) On April 12, 2005,  PricewaterhouseCoopers LLP ("PwC") notified the Audit
Committee of the Board of  Directors of NovaMed,  Inc.  (the  "Company")  of its
decision to resign as the Company's  independent  registered  public  accounting
firm, effective immediately.

(ii) The reports of PwC on the Company's  financial  statements for the past two
fiscal years  contained no adverse opinion or disclaimer of opinion and were not
qualified or modified as to uncertainty, audit scope or accounting principle.

(iii) During the two most recent fiscal years and through April 12, 2005,  there
have been no  disagreements  with PwC on any matter of accounting  principles or
practices,  financial  statement  disclosure,  or auditing  scope or procedures,
which  disagreements,  if not resolved to the  satisfaction  of PwC,  would have
caused them to make reference thereto in its reports on the financial statements
for such years.  During the two most recent  fiscal years and through  April 12,
2005,  there were no  reportable  events (as  defined  in Item  304(a)(1)(v)  of
Regulation S-K).

(iv) The Company has requested PwC to furnish it with a letter  addressed to the
Securities  and Exchange  Commission  stating  whether or not it agrees with the
above  statements  made by the Company in this Form 8-K. A copy of PwC's letter,
dated April 18, 2005, is filed as Exhibit 16.1 to this Form 8-K.

(b) On April 12, 2005,  the Audit  Committee of the Board of Directors  approved
the  appointment  of BDO  Seidman,  LLP  ("BDO")  as the  Company's  independent
registered public accounting firm,  effective  immediately.  During the two most
recent fiscal years and through April 12, 2005, the Company did not consult with
BDO  regarding  (i) the  application  of  accounting  principles  to a specified
transaction,  either completed or proposed;  (ii) the type of audit opinion that
might be rendered on the Company's financial  statements;  and neither a written
report  was  provided  to the  Company  nor oral  advice was  provided  that BDO
concluded  was an  important  factor  considered  by the  Company in  reaching a
decision as to the accounting,  auditing or financial  reporting issue; or (iii)
any matter  that was either the  subject of a  disagreement  (as defined in Item
304(a) (1) (iv) of  Regulation  S-K) or a  reportable  event (as defined in Item
304(a) (1) (v) of Regulation S-K).

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(c)   Exhibits

                  Exhibit Number    Title
                  --------------    -------------

                  16.1              Letter  from  PwC  to  the   Securities  and
                                    Exchange  Commission  dated  April 18,  2005
                                    regarding change in certifying accountant

                  99.1              Press release of NovaMed,  Inc.  dated April
                                    18, 2005
SIGNATURE

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                 NovaMed, Inc.

Dated: April 18, 2005                            By: /s/ Scott T. Macomber
                                                    ----------------------------
                                                    Scott T. Macomber
                                                    Executive Vice President and
                                                    Chief Financial Officer
EXHIBIT INDEX

Exhibit No.       Exhibit
-----------       -------

16.1              Letter  from PwC to the  Securities  and  Exchange  Commission
                  dated April 18, 2005 regarding change in certifying accountant

99.1              Press release of NovaMed, Inc. dated April 18, 2005